VKTX Soars 28% on Q2 Call: Key Takeaways, Pipeline Updates, and What's Next
💥 VKTX up 28% on Q2 Report Out! 🚀
What drove stock move?
⇨ VK2735 oral 💊
» Oral dosing up to 80 mg looks tolerable enough to go to 100 mg
» No more catalyst drought with Obesity Week oral VK2735 readout added in Q4 (see 📸 for updated 2024 readouts)
» Should be an exciting Obesity Week 2024
⇨ VK2735 subq 💉
» Can go right to Ph3 based on FDA feedback - no Ph2b needed
» Testing monthly subq VK2735 based on PK data
⇨ VK2809 in NASH
» Still looking to partner Ph3/MACE
⇨ VK0214 X-ALD
» Still reading out in Q4
⇨ Dual amylin and calcitonin receptor agonist in obesity
» moving into clinic in 2025
⇨ Re partnerships (M&A?) 🤝
» VKTX CEO: “We've been consistent with our receptivity to interests and opportunities and we remain so.”
⇨ Ended quarter with lots of cash - $942M 💰
Fig 1: Obesity Catalyst Watchlist in 2024
Fig 2: VKTX Catalyst (bpiq.com)
This article is not investment or legal advice.
Article history:
First published: 7/27/24 EJV, AV, DG
#VKTX